Chinese Journal of Pharmacovigilance ›› 2018, Vol. 15 ›› Issue (5): 264-267.
Previous Articles Next Articles
QIN Hai-yan,CHEN Li-juan,WU Xiao-li,ZHU Hong,ZHANG Yun,ZHU Hong-chao
Received:
2017-10-24
Revised:
2018-06-21
Online:
2018-05-20
Published:
2018-06-21
Contact:
朱蕻潮,男,硕士,住院医师,心血管疾病的基础及影像学。E-mail:zhuhongchao366@126.com
CLC Number:
QIN Hai-yan,CHEN Li-juan,WU Xiao-li,ZHU Hong,ZHANG Yun,ZHU Hong-chao. Analysis of Adverse Reactions on the Elevated Triglyceride Levels Caused by Tretinoin Tablets in Treatment of Patients with Psoriasis Vulgaris[J]. Chinese Journal of Pharmacovigilance, 2018, 15(5): 264-267.
Add to citation manager EndNote|Ris|BibTeX
[1] 曲彤. 阿维A胶囊联合复方甘草酸苷片治疗寻常型银屑病40例疗效观察[J]. 山西职工医学院学报, 2012, 22(3):43-44. [2] 彭振辉, 牛新武. 维A酸类药物与皮肤病[J]. 中国皮肤性病学杂志, 2004,18(6):374-378. [3] 赵辨. 临床皮肤病学彩色图谱[M]. 南京:江苏科技出版社, 2001:750-762. [4] 王洁, 徐蓉, 李斌. 加味芩珠凉血方联合他扎罗汀凝胶治疗血热证寻常型银屑病的疗效观察[J]. 上海交通大学学报(医学版), 2016, 36(11):1610-1612. [5] 中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J]. 中华心血管病杂志, 2007, 35(5):390-419. [6] 徐风花. 维A酸软膏对于皮肤病的治疗[J].现代养生(下半月版), 2016, (8):103. [7] 金红星. 单芳香维A酸类药物治疗寻常型银屑病效果观察[J]. 白求恩医学杂志, 2015, 13(1):41. [8] 堵建刚. 阿维A酸与甲氨蝶呤治疗寻常型重度银屑病效果比较[J]. 中国乡村医药, 2015, 22(15):17-18. [9] 陈卫丰, 胡伟才. 复方甘草酸苷注射液联合阿维A胶囊治疗红皮病性银屑病的疗效分析[J]. 临床研究, 2015, 4(12):158-159. [10] 周欣, 张锡宝. 维A酸在皮肤科临床应用的现状与进展[J].临床皮肤科杂志, 2011, 40(11):706-709. [11] 梁建梅. 维A酸类药物在皮肤科的临床应用[J]. 医药产业资讯, 2006, 3(12):153-154. [12] 王晓飞, 赵厌平, 陈燕玲. 口服维A酸类药物常见不良反应的观察及护理[J]. 中华护理杂志, 2005, 40(9):688-689. [13] Austin M A. Epidemiology of hypertriglyceridemia and cardiovascular disease[J]. Am J cardiol, 1999, 83(9):13-16. [14] M J, Stampfer,R M, Krauss,J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction[J]. JAMA, 1996, 276(11):882-888. [15] 石亮, 黄娜娜, 孙蓉. 血脂宁药理毒理学研究进展[J]. 中国药物警戒, 2016, 13(6):347-350. [16] Havel R J. The formation of LDL: mechanisms and regulation[J]. Journal of lipid research, 1984, 25(13):1570-1576. [17] LaRosa J C. Cholesterol management in women and the elderly[J]. Journal of internal medicine, 1997, 241(4):307-316. |
[1] | LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850. |
[2] | WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855. |
[3] | XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862. |
[4] | CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875. |
[5] | CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882. |
[6] | ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888. |
[7] | SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895. |
[8] | SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919. |
[9] | YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923. |
[10] | KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927. |
[11] | LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932. |
[12] | LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936. |
[13] | ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940. |
[14] | ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943. |
[15] | CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||